The antigenic anatomy of SARS-CoV-2 receptor binding domain
The EAN is now inviting applications from national neurological societies to co-host the EAN Congress 2029 in Vienna
Increasing Calls for Brain Health Action at High-level New York Event
September 30, 2026
First EAN Annual Report Reviews Major Milestones of 2025
August 7, 2026
Latest Posts
-
-
Breaking newsCOVID-19Research
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
March 3, 2021Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera -
Breaking newsCOVID-19Research
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
March 3, 2021Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape -
Breaking newsCOVID-19Research
Assessing the influence of climate on wintertime SARS-CoV-2 outbreaks
March 3, 2021Assessing the influence of climate on wintertime SARS-CoV-2 outbreaks -
Breaking newsCOVID-19Research
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
March 3, 2021mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants -
Reduction in mobility and COVID-19 transmission
-
Breaking newsCOVID-19Research
Global absence and targeting of protective immune states in severe COVID-19
March 3, 2021Global absence and targeting of protective immune states in severe COVID-19 -
Breaking newsCOVID-19Research
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
March 3, 2021Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study -
Breaking newsCOVID-19Research
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
March 3, 2021Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial -
Breaking newsCOVID-19Research
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial
March 3, 2021Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial -
Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country.
-
Scientific Corner
The Future of Brain Research: EU-Initiatives and Experts Together for a Shared European Brain Research Agenda
March 1, 2021In late 2019, the European Brain Council (EBC) launched the development of the Shared European Brain Research Agenda (SEBRA). -
Paper of the MonthEAN NewsCOVID-19
COVID-19 Paper of the month: A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
March 1, 2021For March 2021, we have selected: Krienke C. et al., A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 2021; 371: 145-153. doi: 10.1126/science.aay3638. -
Clinical Fellowship Reports 2020
-
Other News
EMA public stakeholders meeting on the approval, safety monitoring and impact of COVID-19 vaccines in the EU
March 1, 2021We would like to inform you of the third EMA public stakeholder meeting on the approval, safety monitoring and impact of COVID-19 vaccines in the EU to be held virtually on 26 March 2021 from 13:00 to 15:15 CET.









